GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Cyclically Adjusted Book per Share

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Cyclically Adjusted Book per Share : $21.48 (As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2024 was $26.736. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $21.48 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biomarin Pharmaceutical's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 14.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biomarin Pharmaceutical was 28.40% per year. The lowest was 13.20% per year. And the median was 18.30% per year.

As of today (2024-04-27), Biomarin Pharmaceutical's current stock price is $80.91. Biomarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $21.48. Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is 3.77.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biomarin Pharmaceutical was 27.64. The lowest was 3.77. And the median was 9.05.


Biomarin Pharmaceutical Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted Book per Share Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.44 14.06 16.60 19.12 21.14

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.77 20.33 20.86 21.14 21.48

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Biomarin Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=26.736/129.4194*129.4194
=26.736

Current CPI (Mar. 2024) = 129.4194.

Biomarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 9.941 100.560 12.794
201409 10.231 100.428 13.184
201412 10.248 99.070 13.387
201503 15.132 99.621 19.658
201506 14.639 100.684 18.817
201509 14.220 100.392 18.332
201512 14.864 99.792 19.277
201603 14.116 100.470 18.183
201606 11.744 101.688 14.947
201609 15.410 101.861 19.579
201612 16.023 101.863 20.358
201703 15.978 102.862 20.103
201706 15.952 103.349 19.976
201709 16.032 104.136 19.925
201712 15.972 104.011 19.874
201803 15.890 105.290 19.532
201806 16.253 106.317 19.785
201809 16.385 106.507 19.910
201812 16.650 105.998 20.329
201903 16.403 107.251 19.794
201906 16.502 108.070 19.762
201909 17.118 108.329 20.451
201912 17.362 108.420 20.725
202003 17.924 108.902 21.301
202006 17.868 108.767 21.261
202009 22.336 109.815 26.323
202012 22.593 109.897 26.607
202103 22.784 111.754 26.385
202106 23.137 114.631 26.122
202109 23.240 115.734 25.988
202112 23.194 117.630 25.519
202203 23.749 121.301 25.338
202206 24.291 125.017 25.146
202209 24.585 125.227 25.408
202212 24.715 125.222 25.543
202303 24.835 127.348 25.239
202306 25.420 128.729 25.556
202309 26.000 129.860 25.912
202312 26.255 129.419 26.255
202403 26.736 129.419 26.736

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biomarin Pharmaceutical  (NAS:BMRN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=80.91/21.48
=3.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biomarin Pharmaceutical was 27.64. The lowest was 3.77. And the median was 9.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biomarin Pharmaceutical Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Executives
Jean Jacques Bienaime director, officer: Chief Executive Officer 925 PAGE MILL ROAD, PALO ALTO CA 94304
George Eric Davis officer: VP, General Counsel C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jeffrey Robert Ajer officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs officer: Chief Medical Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
V Bryan Lawlis director
Richard A Meier director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Headlines

From GuruFocus

AMERIPRISE FINANCIAL INC Buys 4, Sells 1 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023

BioMarin to Participate in Three Investor Conferences in March

By PRNewswire PRNewswire 03-02-2023